164.[20230131]Posttransplant assessment of anti–HLA DSA Sensitization
페이지 정보
작성자 신호식 작성일23-02-03 14:21 조회483회 댓글0건관련링크
-
https://youtu.be/zpIdXPay4TU
458회 연결
https://youtu.be/zpIdXPay4TU
본문
첨부한 자료(유튜브 클립, 참고문헌 등)를 학문적 목적으로만 사용해 주시길 부탁드립니다
Review Am J Transplant
. 2023 Jan;23(1):115-132. doi: 10.1016/j.ajt.2022.11.013. Epub 2023 Jan 11.
Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document
Carmen Lefaucheur 1, Kevin Louis 2, Anna B Morris 3, Jean-Luc Taupin 4, Peter Nickerson 5, Anat R Tambur 6, Howard M Gebel 7, Elaine F Reed 8; STAR 2022 Working Group
Collaborators, Affiliations expand
PMID: 36695614 DOI: 10.1016/j.ajt.2022.11.013
Abstract
Although anti-HLA (Human Leukocyte Antigen) donor-specific antibodies (DSAs) are commonly measured in clinical practice and their relationship with transplant outcome is well established, clinical recommendations for anti-HLA antibody assessment are sparse. Supported by a careful and critical review of the current literature performed by the Sensitization in Transplantation: Assessment of Risk 2022 working group, this consensus report provides clinical practice recommendations in kidney, heart, lung, and liver transplantation based on expert assessment of quality and strength of evidence. The recommendations address 3 major clinical problems in transplantation and include guidance regarding posttransplant DSA assessment and application to diagnostics, prognostics, and therapeutics: (1) the clinical implications of positive posttransplant DSA detection according to DSA status (ie, preformed or de novo), (2) the relevance of posttransplant DSA assessment for precision diagnosis of antibody-mediated rejection and for treatment management, and (3) the relevance of posttransplant DSA for allograft prognosis and risk stratification. This consensus report also highlights gaps in current knowledge and provides directions for clinical investigations and trials in the future that will further refine the clinical utility of posttransplant DSA assessment, leading to improved transplant management and patient care.
Keywords: alloantibody; biomarker; clinical research/practice; clinical trial design; endotype; guidelines; histocompatibility; immune monitoring; immunobiology; rejection.
Review Am J Transplant
. 2023 Jan;23(1):115-132. doi: 10.1016/j.ajt.2022.11.013. Epub 2023 Jan 11.
Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document
Carmen Lefaucheur 1, Kevin Louis 2, Anna B Morris 3, Jean-Luc Taupin 4, Peter Nickerson 5, Anat R Tambur 6, Howard M Gebel 7, Elaine F Reed 8; STAR 2022 Working Group
Collaborators, Affiliations expand
PMID: 36695614 DOI: 10.1016/j.ajt.2022.11.013
Abstract
Although anti-HLA (Human Leukocyte Antigen) donor-specific antibodies (DSAs) are commonly measured in clinical practice and their relationship with transplant outcome is well established, clinical recommendations for anti-HLA antibody assessment are sparse. Supported by a careful and critical review of the current literature performed by the Sensitization in Transplantation: Assessment of Risk 2022 working group, this consensus report provides clinical practice recommendations in kidney, heart, lung, and liver transplantation based on expert assessment of quality and strength of evidence. The recommendations address 3 major clinical problems in transplantation and include guidance regarding posttransplant DSA assessment and application to diagnostics, prognostics, and therapeutics: (1) the clinical implications of positive posttransplant DSA detection according to DSA status (ie, preformed or de novo), (2) the relevance of posttransplant DSA assessment for precision diagnosis of antibody-mediated rejection and for treatment management, and (3) the relevance of posttransplant DSA for allograft prognosis and risk stratification. This consensus report also highlights gaps in current knowledge and provides directions for clinical investigations and trials in the future that will further refine the clinical utility of posttransplant DSA assessment, leading to improved transplant management and patient care.
Keywords: alloantibody; biomarker; clinical research/practice; clinical trial design; endotype; guidelines; histocompatibility; immune monitoring; immunobiology; rejection.
